Cargando…

Objective and subjective measures of dalfampridine efficacy in clinical practice

BACKGROUND: Multiple sclerosis affects mobility in over 80% of patients. Dalfampridine is the only approved treatment for walking impairment in multiple sclerosis. We assessed dalfampridine utilization in our practice and investigated response using timed 25 foot walk (T25FW) improvement and a patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Klineova, Sylvia, Farber, Rebecca, Friedman, Joshua, Farrell, Colleen, Lublin, Fred D, Krieger, Stephen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Original Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6077903/ https://www.ncbi.nlm.nih.gov/pubmed/30090641 http://dx.doi.org/10.1177/2055217318786742

Ejemplares similares

Relationship between timed 25-foot walk and diffusion tensor imaging in multiple sclerosis
por: Klineova, Sylvia, et al.
Publicado: (2016)

A Massive Overdose of Dalfampridine
por: Fil, Laura J., et al.
Publicado: (2015)

Clarification of Dalfampridine Labeled Indications
por: Rabinowicz, Adrian L., et al.
Publicado: (2012)

Dalfampridine effects on cognition, fatigue, and dexterity
por: Korsen, Melanie, et al.
Publicado: (2016)

Dalfampridine: Review of its Efficacy in Improving Gait in Patients with Multiple Sclerosis
por: Sahraian, M.A., et al.
Publicado: (2011)

Identification of metabolites of dalfampridine (4-aminopyridine) in dog and rat
por: Caggiano, Anthony, et al.
Publicado: (2013)

Dalfampridine Prior Authorization Program: A Cohort Study
por: Gleason, Patrick P., et al.
Publicado: (2013)

Identification of metabolites of dalfampridine (4-aminopyridine) in human subjects and reaction phenotyping of relevant cytochrome P450 pathways
por: Caggiano, Anthony, et al.
Publicado: (2013)

Differential antibody response to COVID-19 vaccines across immunomodulatory therapies for multiple sclerosis
por: Satyanarayan, Sammita, et al.
Publicado: (2022)

Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis
por: Hayes, Keith C
Publicado: (2011)

Use of Dalfampridine in a Young Child with Episodic Ataxia Type 2
por: Malamud, Emily, et al.
Publicado: (2022)

Treatment patterns and health care resource utilization associated with dalfampridine extended release in multiple sclerosis: a retrospective claims database analysis
por: Guo, Amy, et al.
Publicado: (2016)

Sleep disturbance and memory dysfunction in early multiple sclerosis
por: Sumowski, James F., et al.
Publicado: (2021)

Dalfampridine sustained-release for symptomatic improvement of walking speed in patients with multiple sclerosis
por: Jeffery, Douglas R, et al.
Publicado: (2010)

Oral Dalfampridine Improves Standing Balance Detected at Static Posturography in Multiple Sclerosis
por: Prosperini, Luca, et al.
Publicado: (2014)

Dalfampridine extended release tablets: 1 year of postmarketing safety experience in the US
por: Jara, Michele, et al.
Publicado: (2013)

Dalfampridine is associated with de novo occurrence or reoccurrence of positive sensory symptoms in MS
por: Solaro, C., et al.
Publicado: (2015)

Randomized, Placebo-controlled Crossover Study of Dalfampridine Extended-release in Transverse Myelitis
por: Schwartz, Kateryna, et al.
Publicado: (2017)

Study on Dalfampridine in the treatment of Multiple Sclerosis Mobility Disability: A meta-analysis
por: Shi, Jianzhen, et al.
Publicado: (2019)

Dalfampridine in the treatment of multiple sclerosis: a meta-analysis of randomised controlled trials
por: Zhang, Enyao, et al.
Publicado: (2021)

Pharmacokinetics of Dalfampridine Extended Release 7.5-mg Tablets in Healthy Subjects and Individuals With Mild and Moderate Renal Impairment: An Open-Label Study
por: Samara, Emil, et al.
Publicado: (2014)

The effectiveness of amantadine and dalfampridine in improving fatigue in patients with multiple sclerosis: A randomized, double-blind, clinical trial
por: Sadeqi, Yasaman, et al.
Publicado: (2022)

Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials
por: Goodman, Andrew D, et al.
Publicado: (2015)

Patient Perspectives and Experience with Dalfampridine Treatment in Multiple Sclerosis-Related Walking Impairment: The Step Together Program
por: Crayton, Heidi, et al.
Publicado: (2014)

Safety profile of dalfampridine extended release in multiple sclerosis: 5-year postmarketing experience in the United States
por: Jara, Michele, et al.
Publicado: (2015)

Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system
por: Xiong, Rui, et al.
Publicado: (2023)

Cerebellar volume as imaging outcome in progressive multiple sclerosis
por: Inglese, Matilde, et al.
Publicado: (2017)

A double-blind, randomized, controlled study of two dose strengths of dalfampridine extended release on walking deficits in ischemic stroke
por: Page, Stephen J., et al.
Publicado: (2020)

Prescriber utilization of dalfampridine extended release tablets in multiple sclerosis: a retrospective pharmacy and medical claims analysis
por: Jara, Michele, et al.
Publicado: (2014)

Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy
por: Katz Sand, Ilana, et al.
Publicado: (2023)

Estimation of the effect of dalfampridine-ER on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients
por: Limone, Brendan L, et al.
Publicado: (2013)

Increasing Patient Safety Among Multiple Sclerosis (MS) Drug Dalfampridine Users by Expanding Awareness of the Serious Side Effects
por: Zaman, Rameez, et al.
Publicado: (2022)

Objective and Subjective Measurement of Cough in Asthma: A Systematic Review of the Literature
por: Holmes, Joshua, et al.
Publicado: (2022)

Objective and Measurable Biomarkers in Chronic Subjective Tinnitus
por: Kang, Dae-Woong, et al.
Publicado: (2021)

Subjective and objective measures of visual awareness converge
por: Kiefer, Markus, et al.
Publicado: (2023)

Subjective and objective measurements of nurses’ stress and recovery
por: Rantanen, N, et al.
Publicado: (2023)

Motor Performance Assessment in Parkinson’s Disease: Association between Objective In-Clinic, Objective In-Home, and Subjective/Semi-Objective Measures
por: Toosizadeh, Nima, et al.
Publicado: (2015)

Inclusion in limited distribution drug network reduces time to dalfampridine access in patients with multiple sclerosis at a health-system specialty pharmacy
por: Peter, Megan E, et al.
Publicado: (2021)

Phase-Sensitive Inversion-Recovery MRI Improves Longitudinal Cortical Lesion Detection in Progressive MS
por: Harel, Asaff, et al.
Publicado: (2016)

Emergency Medical Care of Multiple Sclerosis Patients: Primary Data from the Mount Sinai Resource Utilization in Multiple Sclerosis Project
por: Oynhausen, Svenja, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_822miqb7h4js11m28rpjv0rf2v